Global Hospital Acquired Disease Testing- Market

Hospital Acquired Disease Testing- Comprehensive Study by Type (Urinary Tract Infection, Pneumonia, Bloodstream, Surgical Site, Other), Drugs (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), End-users (Hospitals, Intensive Care Units, Ambulatory Surgical, Diagnostic Centers, Nursing Homes, Maternity Centers, Others), Testing (Microbial Testing Instruments, Reagents and Consumables, Infection Prevention, Surveillance Software) Players and Region - Global Market Outlook to 2030

Hospital Acquired Disease Testing- Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 14.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hospital Acquired Disease Testing-
Infections obtained in hospitals and medical clinics are known as hospital acquired infections (HAIs) or nosocomial infections. Infections or diseases that start in a hospital are referred to as nosocomial. Hospital-acquired infections (HAI) are nosocomially acquired illnesses that are usually not present or are incubating at the time of admission. These infections are frequently acquired after being admitted to the hospital and manifest 48 hours later.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR14.7%


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Hospital Acquired Disease Testing- market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Life Technologies (United States), Luminex Corporation (United States), Diatherix Laboratories (United States), Meridian Biosciences (United States), Qiagen GmbH (Germany), Cantel Medical Corporation (United States), F.Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (United States), Cepheid (United States) and Siemens Healthcare (Germany) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Hospital Acquired Disease Testing- market by Type (Urinary Tract Infection, Pneumonia, Bloodstream, Surgical Site and Other) and Region.



On the basis of geography, the market of Hospital Acquired Disease Testing- has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Antibacterial Drugs will boost the Hospital Acquired Disease Testing- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Hospital Acquired Disease Testing- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Testing, the sub-segment i.e. Microbial Testing Instruments will boost the Hospital Acquired Disease Testing- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Development of Technologically Advanced Diagnostic Products

Market Growth Drivers:
Increasing the Demand for Diagnosis and Rising Geriatric Population

Challenges:
Hospital Staff Complacency and Increase in Multi-drug Resistance Pathogens

Restraints:
Absence of Effective Programs and Strict Policies in African and other Under-developed Countries

Opportunities:
Decreasing Prevalence of Nosocomial Infections in the Developed Countries owing to Improved Healthcare Infrastructure

Market Leaders and their expansionary development strategies
In March 2023, Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc.
In May 2022, WHO launches first ever global report on infection prevention and control, The COVID-19 pandemic and other recent large disease outbreaks have highlighted the extent to which health care settings can contribute to the spread of infections, harming patients, health workers and visitors, if insufficient attention is paid to infection prevention and control (IPC).


Key Target Audience
Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Urinary Tract Infection
  • Pneumonia
  • Bloodstream
  • Surgical Site
  • Other
By Drugs
  • Antibacterial Drugs
  • Antiviral Drugs
  • Antifungal Drugs

By End-users
  • Hospitals
  • Intensive Care Units
  • Ambulatory Surgical
  • Diagnostic Centers
  • Nursing Homes
  • Maternity Centers
  • Others

By Testing
  • Microbial Testing Instruments
  • Reagents and Consumables
  • Infection Prevention
  • Surveillance Software

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing the Demand for Diagnosis
      • 3.2.2. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Hospital Staff Complacency
      • 3.3.2. Increase in Multi-drug Resistance Pathogens
    • 3.4. Market Trends
      • 3.4.1. Development of Technologically Advanced Diagnostic Products
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hospital Acquired Disease Testing-, by Type, Drugs, End-users, Testing and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hospital Acquired Disease Testing- (Value)
      • 5.2.1. Global Hospital Acquired Disease Testing- by: Type (Value)
        • 5.2.1.1. Urinary Tract Infection
        • 5.2.1.2. Pneumonia
        • 5.2.1.3. Bloodstream
        • 5.2.1.4. Surgical Site
        • 5.2.1.5. Other
      • 5.2.2. Global Hospital Acquired Disease Testing- by: Drugs (Value)
        • 5.2.2.1. Antibacterial Drugs
        • 5.2.2.2. Antiviral Drugs
        • 5.2.2.3. Antifungal Drugs
      • 5.2.3. Global Hospital Acquired Disease Testing- by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Intensive Care Units
        • 5.2.3.3. Ambulatory Surgical
        • 5.2.3.4. Diagnostic Centers
        • 5.2.3.5. Nursing Homes
        • 5.2.3.6. Maternity Centers
        • 5.2.3.7. Others
      • 5.2.4. Global Hospital Acquired Disease Testing- by: Testing (Value)
        • 5.2.4.1. Microbial Testing Instruments
        • 5.2.4.2. Reagents and Consumables
        • 5.2.4.3. Infection Prevention
        • 5.2.4.4. Surveillance Software
      • 5.2.5. Global Hospital Acquired Disease Testing- Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hospital Acquired Disease Testing-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Life Technologies (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Luminex Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Diatherix Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Meridian Biosciences (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Qiagen GmbH (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cantel Medical Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F.Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cepheid (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Siemens Healthcare (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hospital Acquired Disease Testing- Sale, by Type, Drugs, End-users, Testing and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hospital Acquired Disease Testing- (Value)
      • 7.2.1. Global Hospital Acquired Disease Testing- by: Type (Value)
        • 7.2.1.1. Urinary Tract Infection
        • 7.2.1.2. Pneumonia
        • 7.2.1.3. Bloodstream
        • 7.2.1.4. Surgical Site
        • 7.2.1.5. Other
      • 7.2.2. Global Hospital Acquired Disease Testing- by: Drugs (Value)
        • 7.2.2.1. Antibacterial Drugs
        • 7.2.2.2. Antiviral Drugs
        • 7.2.2.3. Antifungal Drugs
      • 7.2.3. Global Hospital Acquired Disease Testing- by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Intensive Care Units
        • 7.2.3.3. Ambulatory Surgical
        • 7.2.3.4. Diagnostic Centers
        • 7.2.3.5. Nursing Homes
        • 7.2.3.6. Maternity Centers
        • 7.2.3.7. Others
      • 7.2.4. Global Hospital Acquired Disease Testing- by: Testing (Value)
        • 7.2.4.1. Microbial Testing Instruments
        • 7.2.4.2. Reagents and Consumables
        • 7.2.4.3. Infection Prevention
        • 7.2.4.4. Surveillance Software
      • 7.2.5. Global Hospital Acquired Disease Testing- Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hospital Acquired Disease Testing-: by Type(USD Million)
  • Table 2. Hospital Acquired Disease Testing- Urinary Tract Infection , by Region USD Million (2018-2023)
  • Table 3. Hospital Acquired Disease Testing- Pneumonia , by Region USD Million (2018-2023)
  • Table 4. Hospital Acquired Disease Testing- Bloodstream , by Region USD Million (2018-2023)
  • Table 5. Hospital Acquired Disease Testing- Surgical Site , by Region USD Million (2018-2023)
  • Table 6. Hospital Acquired Disease Testing- Other , by Region USD Million (2018-2023)
  • Table 7. Hospital Acquired Disease Testing-: by Drugs(USD Million)
  • Table 8. Hospital Acquired Disease Testing- Antibacterial Drugs , by Region USD Million (2018-2023)
  • Table 9. Hospital Acquired Disease Testing- Antiviral Drugs , by Region USD Million (2018-2023)
  • Table 10. Hospital Acquired Disease Testing- Antifungal Drugs , by Region USD Million (2018-2023)
  • Table 11. Hospital Acquired Disease Testing-: by End-users(USD Million)
  • Table 12. Hospital Acquired Disease Testing- Hospitals , by Region USD Million (2018-2023)
  • Table 13. Hospital Acquired Disease Testing- Intensive Care Units , by Region USD Million (2018-2023)
  • Table 14. Hospital Acquired Disease Testing- Ambulatory Surgical , by Region USD Million (2018-2023)
  • Table 15. Hospital Acquired Disease Testing- Diagnostic Centers , by Region USD Million (2018-2023)
  • Table 16. Hospital Acquired Disease Testing- Nursing Homes , by Region USD Million (2018-2023)
  • Table 17. Hospital Acquired Disease Testing- Maternity Centers , by Region USD Million (2018-2023)
  • Table 18. Hospital Acquired Disease Testing- Others , by Region USD Million (2018-2023)
  • Table 19. Hospital Acquired Disease Testing-: by Testing(USD Million)
  • Table 20. Hospital Acquired Disease Testing- Microbial Testing Instruments , by Region USD Million (2018-2023)
  • Table 21. Hospital Acquired Disease Testing- Reagents and Consumables , by Region USD Million (2018-2023)
  • Table 22. Hospital Acquired Disease Testing- Infection Prevention , by Region USD Million (2018-2023)
  • Table 23. Hospital Acquired Disease Testing- Surveillance Software , by Region USD Million (2018-2023)
  • Table 24. South America Hospital Acquired Disease Testing-, by Country USD Million (2018-2023)
  • Table 25. South America Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 26. South America Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 27. South America Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 28. South America Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 29. Brazil Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 30. Brazil Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 31. Brazil Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 32. Brazil Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 33. Argentina Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 34. Argentina Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 35. Argentina Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 36. Argentina Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 37. Rest of South America Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 38. Rest of South America Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 39. Rest of South America Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 40. Rest of South America Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 41. Asia Pacific Hospital Acquired Disease Testing-, by Country USD Million (2018-2023)
  • Table 42. Asia Pacific Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 43. Asia Pacific Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 44. Asia Pacific Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 45. Asia Pacific Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 46. China Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 47. China Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 48. China Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 49. China Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 50. Japan Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 51. Japan Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 52. Japan Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 53. Japan Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 54. India Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 55. India Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 56. India Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 57. India Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 58. South Korea Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 59. South Korea Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 60. South Korea Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 61. South Korea Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 62. Australia Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 63. Australia Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 64. Australia Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 65. Australia Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 70. Europe Hospital Acquired Disease Testing-, by Country USD Million (2018-2023)
  • Table 71. Europe Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 72. Europe Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 73. Europe Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 74. Europe Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 75. Germany Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 76. Germany Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 77. Germany Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 78. Germany Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 79. France Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 80. France Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 81. France Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 82. France Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 83. Italy Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 84. Italy Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 85. Italy Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 86. Italy Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 87. United Kingdom Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 88. United Kingdom Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 89. United Kingdom Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 90. United Kingdom Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 91. Netherlands Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 92. Netherlands Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 93. Netherlands Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 94. Netherlands Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 95. Rest of Europe Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 96. Rest of Europe Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 97. Rest of Europe Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 98. Rest of Europe Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 99. MEA Hospital Acquired Disease Testing-, by Country USD Million (2018-2023)
  • Table 100. MEA Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 101. MEA Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 102. MEA Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 103. MEA Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 104. Middle East Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 105. Middle East Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 106. Middle East Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 107. Middle East Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 108. Africa Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 109. Africa Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 110. Africa Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 111. Africa Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 112. North America Hospital Acquired Disease Testing-, by Country USD Million (2018-2023)
  • Table 113. North America Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 114. North America Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 115. North America Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 116. North America Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 117. United States Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 118. United States Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 119. United States Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 120. United States Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 121. Canada Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 122. Canada Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 123. Canada Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 124. Canada Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 125. Mexico Hospital Acquired Disease Testing-, by Type USD Million (2018-2023)
  • Table 126. Mexico Hospital Acquired Disease Testing-, by Drugs USD Million (2018-2023)
  • Table 127. Mexico Hospital Acquired Disease Testing-, by End-users USD Million (2018-2023)
  • Table 128. Mexico Hospital Acquired Disease Testing-, by Testing USD Million (2018-2023)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Hospital Acquired Disease Testing-: by Type(USD Million)
  • Table 140. Hospital Acquired Disease Testing- Urinary Tract Infection , by Region USD Million (2025-2030)
  • Table 141. Hospital Acquired Disease Testing- Pneumonia , by Region USD Million (2025-2030)
  • Table 142. Hospital Acquired Disease Testing- Bloodstream , by Region USD Million (2025-2030)
  • Table 143. Hospital Acquired Disease Testing- Surgical Site , by Region USD Million (2025-2030)
  • Table 144. Hospital Acquired Disease Testing- Other , by Region USD Million (2025-2030)
  • Table 145. Hospital Acquired Disease Testing-: by Drugs(USD Million)
  • Table 146. Hospital Acquired Disease Testing- Antibacterial Drugs , by Region USD Million (2025-2030)
  • Table 147. Hospital Acquired Disease Testing- Antiviral Drugs , by Region USD Million (2025-2030)
  • Table 148. Hospital Acquired Disease Testing- Antifungal Drugs , by Region USD Million (2025-2030)
  • Table 149. Hospital Acquired Disease Testing-: by End-users(USD Million)
  • Table 150. Hospital Acquired Disease Testing- Hospitals , by Region USD Million (2025-2030)
  • Table 151. Hospital Acquired Disease Testing- Intensive Care Units , by Region USD Million (2025-2030)
  • Table 152. Hospital Acquired Disease Testing- Ambulatory Surgical , by Region USD Million (2025-2030)
  • Table 153. Hospital Acquired Disease Testing- Diagnostic Centers , by Region USD Million (2025-2030)
  • Table 154. Hospital Acquired Disease Testing- Nursing Homes , by Region USD Million (2025-2030)
  • Table 155. Hospital Acquired Disease Testing- Maternity Centers , by Region USD Million (2025-2030)
  • Table 156. Hospital Acquired Disease Testing- Others , by Region USD Million (2025-2030)
  • Table 157. Hospital Acquired Disease Testing-: by Testing(USD Million)
  • Table 158. Hospital Acquired Disease Testing- Microbial Testing Instruments , by Region USD Million (2025-2030)
  • Table 159. Hospital Acquired Disease Testing- Reagents and Consumables , by Region USD Million (2025-2030)
  • Table 160. Hospital Acquired Disease Testing- Infection Prevention , by Region USD Million (2025-2030)
  • Table 161. Hospital Acquired Disease Testing- Surveillance Software , by Region USD Million (2025-2030)
  • Table 162. South America Hospital Acquired Disease Testing-, by Country USD Million (2025-2030)
  • Table 163. South America Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 164. South America Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 165. South America Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 166. South America Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 167. Brazil Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 168. Brazil Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 169. Brazil Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 170. Brazil Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 171. Argentina Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 172. Argentina Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 173. Argentina Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 174. Argentina Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 175. Rest of South America Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 176. Rest of South America Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 177. Rest of South America Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 178. Rest of South America Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 179. Asia Pacific Hospital Acquired Disease Testing-, by Country USD Million (2025-2030)
  • Table 180. Asia Pacific Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 181. Asia Pacific Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 182. Asia Pacific Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 183. Asia Pacific Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 184. China Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 185. China Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 186. China Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 187. China Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 188. Japan Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 189. Japan Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 190. Japan Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 191. Japan Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 192. India Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 193. India Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 194. India Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 195. India Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 196. South Korea Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 197. South Korea Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 198. South Korea Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 199. South Korea Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 200. Australia Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 201. Australia Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 202. Australia Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 203. Australia Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 208. Europe Hospital Acquired Disease Testing-, by Country USD Million (2025-2030)
  • Table 209. Europe Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 210. Europe Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 211. Europe Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 212. Europe Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 213. Germany Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 214. Germany Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 215. Germany Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 216. Germany Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 217. France Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 218. France Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 219. France Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 220. France Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 221. Italy Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 222. Italy Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 223. Italy Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 224. Italy Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 225. United Kingdom Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 226. United Kingdom Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 227. United Kingdom Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 228. United Kingdom Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 229. Netherlands Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 230. Netherlands Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 231. Netherlands Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 232. Netherlands Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 233. Rest of Europe Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 234. Rest of Europe Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 235. Rest of Europe Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 236. Rest of Europe Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 237. MEA Hospital Acquired Disease Testing-, by Country USD Million (2025-2030)
  • Table 238. MEA Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 239. MEA Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 240. MEA Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 241. MEA Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 242. Middle East Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 243. Middle East Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 244. Middle East Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 245. Middle East Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 246. Africa Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 247. Africa Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 248. Africa Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 249. Africa Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 250. North America Hospital Acquired Disease Testing-, by Country USD Million (2025-2030)
  • Table 251. North America Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 252. North America Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 253. North America Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 254. North America Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 255. United States Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 256. United States Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 257. United States Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 258. United States Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 259. Canada Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 260. Canada Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 261. Canada Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 262. Canada Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 263. Mexico Hospital Acquired Disease Testing-, by Type USD Million (2025-2030)
  • Table 264. Mexico Hospital Acquired Disease Testing-, by Drugs USD Million (2025-2030)
  • Table 265. Mexico Hospital Acquired Disease Testing-, by End-users USD Million (2025-2030)
  • Table 266. Mexico Hospital Acquired Disease Testing-, by Testing USD Million (2025-2030)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hospital Acquired Disease Testing-: by Type USD Million (2018-2023)
  • Figure 5. Global Hospital Acquired Disease Testing-: by Drugs USD Million (2018-2023)
  • Figure 6. Global Hospital Acquired Disease Testing-: by End-users USD Million (2018-2023)
  • Figure 7. Global Hospital Acquired Disease Testing-: by Testing USD Million (2018-2023)
  • Figure 8. South America Hospital Acquired Disease Testing- Share (%), by Country
  • Figure 9. Asia Pacific Hospital Acquired Disease Testing- Share (%), by Country
  • Figure 10. Europe Hospital Acquired Disease Testing- Share (%), by Country
  • Figure 11. MEA Hospital Acquired Disease Testing- Share (%), by Country
  • Figure 12. North America Hospital Acquired Disease Testing- Share (%), by Country
  • Figure 13. Global Hospital Acquired Disease Testing- share by Players 2023 (%)
  • Figure 14. Global Hospital Acquired Disease Testing- share by Players (Top 3) 2023(%)
  • Figure 15. Global Hospital Acquired Disease Testing- share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Life Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 18. Life Technologies (United States) Revenue: by Geography 2023
  • Figure 19. Luminex Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 20. Luminex Corporation (United States) Revenue: by Geography 2023
  • Figure 21. Diatherix Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 22. Diatherix Laboratories (United States) Revenue: by Geography 2023
  • Figure 23. Meridian Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 24. Meridian Biosciences (United States) Revenue: by Geography 2023
  • Figure 25. Qiagen GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Qiagen GmbH (Germany) Revenue: by Geography 2023
  • Figure 27. Cantel Medical Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Cantel Medical Corporation (United States) Revenue: by Geography 2023
  • Figure 29. F.Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F.Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 31. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 32. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 33. Cepheid (United States) Revenue, Net Income and Gross profit
  • Figure 34. Cepheid (United States) Revenue: by Geography 2023
  • Figure 35. Siemens Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Siemens Healthcare (Germany) Revenue: by Geography 2023
  • Figure 37. Global Hospital Acquired Disease Testing-: by Type USD Million (2025-2030)
  • Figure 38. Global Hospital Acquired Disease Testing-: by Drugs USD Million (2025-2030)
  • Figure 39. Global Hospital Acquired Disease Testing-: by End-users USD Million (2025-2030)
  • Figure 40. Global Hospital Acquired Disease Testing-: by Testing USD Million (2025-2030)
  • Figure 41. South America Hospital Acquired Disease Testing- Share (%), by Country
  • Figure 42. Asia Pacific Hospital Acquired Disease Testing- Share (%), by Country
  • Figure 43. Europe Hospital Acquired Disease Testing- Share (%), by Country
  • Figure 44. MEA Hospital Acquired Disease Testing- Share (%), by Country
  • Figure 45. North America Hospital Acquired Disease Testing- Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Life Technologies (United States)
  • Luminex Corporation (United States)
  • Diatherix Laboratories (United States)
  • Meridian Biosciences (United States)
  • Qiagen GmbH (Germany)
  • Cantel Medical Corporation (United States)
  • F.Hoffmann-La Roche Ltd. (Switzerland)
  • Abbott Laboratories (United States)
  • Cepheid (United States)
  • Siemens Healthcare (Germany)
Select User Access Type

Key Highlights of Report


Mar 2024 247 Pages 65 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hospital Acquired Disease Testing- Market Quantitative research analysis
Global Hospital Acquired Disease Testing- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Life Technologies (United States), Luminex Corporation (United States), Diatherix Laboratories (United States), Meridian Biosciences (United States), Qiagen GmbH (Germany), Cantel Medical Corporation (United States), F.Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (United States), Cepheid (United States) and Siemens Healthcare (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Development of Technologically Advanced Diagnostic Products" is seen as one of major influencing trends for Hospital Acquired Disease Testing- Market during projected period 2023-2030.
The Hospital Acquired Disease Testing- market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hospital Acquired Disease Testing- Market Report?

Have a Query? Click Here

Other Related Reports

Pendred Syndrome Comprehensive Study by Type (Sensorineural hearing loss,, Conductive hearing loss, Mixed hearing loss), Application (Hearing aids for children with the condition.), Treatment (Radioa...
$ 3800
Mandibular Implants Comprehensive Study by End-users (Hospitals, Dental Clinics, Academic & Research Institutes), Material (Titanium Implants, Zirconium Implants), Dental Implants (Two-Stage Dental I...
$ 3800
Mud therapy Comprehensive Study by Type (Black Mud, Dead Sea Mud, Moor Mud, Silt sulphide Mud, Sapropelic Mud, Others), Application (Psoriasis, Leucoderma, Leprosy, Rheumatic Pain, Others), Treatment...
$ 3500
Klippel Trenaunay Syndrome Treatment Comprehensive Study by Therapy (Laser Therapy, Sclero Therapy, Compression Therapy, Physical Therapy, Others), Treatment (Medication, Surgery, Orthopedic Devices,...
$ 3500
IHC Daignostics Comprehensive Study by Type (Antibodies (Primary antibodies, Secondary antibodies), Reagents (Histological Stains, Blocking Sera, and Reagents, Chromogenic Substrates, Fixation Reagen...
$ 3800
Clostridium Vaccine Animal Health Comprehensive Study by Distribution Channel (Veterinary Clinic, Veterinary Hospital, Veterinary Research institute, Retail Pharmacy), Animal Species (Bovine, Ovine, ...
$ 3500